Conjudates of Pyrrolo[1,4]Benzodiazepine Dimers As Anticancer Agents

Sanofi

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 4 of these applications claim priority to application PCT/IB2010/054866, filed Oct 27, 2010. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

Patent	Title	Holder	Status	Expires	Time remaining	Confidence
US 8,481,042	Conjudates of Pyrrolo[1,4]Benzodiazepine Dimers As Anticancer Agents Sanofi In force Term ends Aug 12, 2030 · High confidence	Sanofi	In force	Term ends Aug 12, 2030	Term ends Aug 12, 2030	High confidence
US 8,927,592	Novel Antitumoral Use of Cabazitaxel Sanofi Mature IP In force Term ends Oct 27, 2030 · Medium confidence	Sanofi Mature IP	In force	Term ends Oct 27, 2030	Term ends Oct 27, 2030	Medium confidence
US 10,583,110	Novel Antitumoral Use of Cabazitaxel Sanofi Mature IP In force Term ends Oct 27, 2030 · High confidence	Sanofi Mature IP	In force	Term ends Oct 27, 2030	Term ends Oct 27, 2030	High confidence
US 10,716,777	Novel Antitumoral Use of Cabazitaxel Sanofi Mature IP In force Ends no later than Oct 27, 2030 · Medium confidence	Sanofi Mature IP	In force	Ends no later than Oct 27, 2030	Ends no later than Oct 27, 2030	Medium confidence
US 12,453,712	Novel Antitumoral Use of Cabazitaxel Sanofi Mature IP In force Term ends Oct 27, 2030 · Low confidence	Sanofi Mature IP	In force	Term ends Oct 27, 2030	Term ends Oct 27, 2030	Low confidence
US 8,518,947	NOVEL (HETEROCYCLE/TETRAHYDROPYRIDINE)-(PIPERAZINYL)-1-Alcanone AND (HETEROCYCLE/DIHYDROPYRROLIDINE)-(PIPERAZINYL)-1-Alcanone DERIVATIVES, AND USE THEREOF AS p75 INHIBITORS Sanofi In force Term ends Dec 13, 2030 · High confidence	Sanofi	In force	Term ends Dec 13, 2030	Term ends Dec 13, 2030	High confidence
US 8,580,790	NOVEL (HETEROCYCLE/CONDENSED PIPERIDINE)-(PIPERAZINYL)-1-Alkanone OR (HETEROCYCLE/CONDENSED PYRROLIDINE)-(PIPERAZINYL)-1-Alkanone DERIVATIVES AND USE THEREOF AS p75 INHIBITORS Sanofi In force Term ends Dec 13, 2030 · High confidence	Sanofi	In force	Term ends Dec 13, 2030	Term ends Dec 13, 2030	High confidence
US 8,906,924	NOVEL (HETEROCYCLE/TETRAHYDROPYRIDINE)-(PIPERAZINYL)-1-Alcanone AND (HETEROCYCLE/DIHYDROPYRROLIDINE)-(PIPERAZINYL)-1-Alcanone DERIVATIVES, AND USE THEREOF AS p75 INHIBITORS Sanofi In force Term ends Dec 13, 2030 · Medium confidence	Sanofi	In force	Term ends Dec 13, 2030	Term ends Dec 13, 2030	Medium confidence
US 8,957,211	Novel (Heterocycle/Condensed PIPERIDINE)-(PIPERAZINYL)-1-Alkanone or (Heterocycle/Condensed PYRROLIDINE)-(PIPERAZINYL)-1-Alkanone Derivatives and Use Thereof as P75 Inhibitors Sanofi In force Term ends Dec 13, 2030 · Medium confidence	Sanofi	In force	Term ends Dec 13, 2030	Term ends Dec 13, 2030	Medium confidence
US 8,461,175	1-Pyrazolo[4,3-c]isoquinoline Derivatives, Preparation Thereof and Therapeutic Use Thereof Sanofi Lapsed Jun 11, 2021 on the fee record Ended Jun 11, 2021 · High confidence	Sanofi	Lapsed Jun 11, 2021 on the fee record	Ended Jun 11, 2021	Ended Jun 11, 2021	High confidence
14 more patents in this group · Pro

10 of 24 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

Pro members see all 24, including 8 expired.

Upgrade to Pro

9 of these are in force and held by Sanofi.

Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.